James R Howard-Tripp – Chief Executive Officer
Mr. Howard-Tripp has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation (Allelix, Labopharm, Dermacor) of several successful companies. He has 13 years’ experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently, as President and CEO of Labopharm, he oversaw the research, development and approval of 3 products and the launch of 2, with the lead product marketed in 19 countries (total end user sales approximately $100 million). During his tenure, Labopharm raised >$250 million in the public markets (US IPO $112 million in 2006) and achieved >$100 million in deal revenue (partners included: Sanofi-Aventis, Purdue Pharma, Merck Inc., Grunenthal, Angelini and Esteve). Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.
Leslie Auld, MBA, CPA, CA – Chief Financial Officer
Ms. Auld began her professional career in 1991 with PriceWaterhouseCoopers. She later joined Helix BioPharma Corp. where she progressed from Controller to Chief Financial Officer. In 2004, she joined Luminex Diagnostics (formerly TM BioScience Corp.) as Senior Director of Finance, where she focused on finance and operations during a period of growth and then held a pivotal role in the transaction that took TM BioScience private when it was acquired by Luminex. Ms. Auld joined Attwell Capital Inc. (formerly Fralex Therapeutics) as Chief Financial Officer in 2007. She left that position in June 2009 but continued to support Attwell and other issuers in a consulting capacity. A Chartered Accountant, Ms. Auld graduated with an Honors Bachelor of Science, Pharmacology & Toxicology from the University of Western Ontario, and has a Master of Business Administration degree from the University of Toronto.
Karl Florence – Senior Director of Reimbursment Mr. Florence joined Innovative Diagnostic Laboratory in March of 2015. Karl has more than twenty years of experience in the medical device and diagnostic industry, having held various positions in sales, sales management, managed care, managed care contracting on a national level, reimbursement strategy, and new technology acceptance and payment for both large corporations and start-up medical device companies. He has secured CPT codes for MiniMed and Conceptus devices and Vermillion’s multi-analyte diagnostic test and HCPCS supply codes for DexCom’s glucose sensor products. He has been responsible for evidence development and key opinion leader interactions with regional and national payers for coverage determinations.
Joanna M. Halsey, Esq. – Chief Compliance Officer
Ms. Halsey is the Chief Compliance Officer and General Counsel for IDL. She joined the company in 2014. Ms. Halsey began her career in private practice as an associate at Hunton & Williams, one of the nation’s largest law firms. After eight years in private practice, she became in-house counsel and Vice President of a Fortune 500 company providing legal advice and counsel to senior executives on issues such as benefit plan administration, IRS reporting and disclosure requirements, federal and state employment laws, incentive agreements, stock options, executive compensation, mergers and acquisitions, workplace planning, vendor contracts, settling civil litigation issues, and workplace investigations. Ms. Halsey also worked for the Federal Reserve System and was a member of its cross district Business Value Leadership Team. A licensed attorney, Ms. Halsey earned a BA degree with honors from Meredith College with a double major in History and Political Studies, and a Juris Doctor degree with honors from the University of Richmond, T.C. Williams School of Law.
James H. Brennan, MBA is the Corporate Controller for Innovative Diagnostic Laboratory, LLP. He joined the Company in April 2015. Mr. Brennan began his career with the Coca Cola Bottling Company as Plant Controller, Systems Analyst, and Corporate Accounting Manager. Mr. Brennan’s other work experience included corporate controller positions for Star Tobacco and Pharmaceuticals, Herald Pharmaceuticals, Delta Airport Consultants, Christian Children’s Fund, BOSH Global Systems and KRS Holdings. Mr. Brennan joined Commonwealth Biotechnologies, Inc., a publicly traded company as a corporate controller and was promoted to Vice President of Financial Operations. His career also included work for Northfield Medical as the Director of Finance and Administration, a medical repair facility.